Page last updated: 2024-12-06

3,4-dimethoxy-5-hydroxybenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-Dimethoxy-5-hydroxybenzoic acid, also known as syringic acid, is a naturally occurring phenolic compound found in various plants, including coffee, tea, and berries. It exhibits antioxidant and anti-inflammatory properties, and has been studied for its potential therapeutic benefits in conditions like cancer and diabetes. The compound can be synthesized through various methods, including oxidation of syringaldehyde or enzymatic hydrolysis of lignin. Its biological activity is attributed to its ability to scavenge free radicals and inhibit inflammatory pathways. Research on syringic acid focuses on its potential applications in medicine, food science, and cosmetics, as well as its role in plant defense mechanisms.'
```

3,4-dimethoxy-5-hydroxybenzoic acid: thiopurine methyltransferase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74709
CHEMBL ID85234
CHEBI ID88603
SCHEMBL ID503998
MeSH IDM0118818

Synonyms (36)

Synonym
CHEMBL85234 ,
chebi:88603 ,
5-hydroxy veratric acid
nsc19885
1916-08-1
nsc-19885
3-hydroxy-4,5-dimethoxybenzoic acid
3,4-dimethoxy-5-hydroxy benzoic acid
3,4-dimethoxy-5-hydroxybenzoic acid
inchi=1/c9h10o5/c1-13-7-4-5(9(11)12)3-6(10)8(7)14-2/h3-4,10h,1-2h3,(h,11,12
AKOS000277314
5-hydroxy-3,4-dimethoxybenzoic acid
unii-j6fh4n7rmw
einecs 217-630-9
j6fh4n7rmw ,
nsc 19885
bdbm50405316
FT-0633909
BRD-K13195996-001-01-2
3-hydroxy-4,5-dimethoxy-benzoic acid
SCHEMBL503998
W-107729
5-hydroxyveratric acid
benzoic acid, 3-hydroxy-4,5-dimethoxy-
DTXSID90172689
mfcd00002508
3,4-o-dimethylgallic acid
AS-62460
3-hydroxy-4 5-dimethoxybenzoic acid
Q27160492
gallic acid, 3,4-dimethyl ether
veratric acid, 5-hydroxy-
E79016
3-hydroxy-4,5-dimethoxybenzoicacid
5-hydroxy-3,4-dimethoxybenzoicacid
CS-0328421
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
trihydroxybenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
methylationThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic catabolic processThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingThiopurine S-methyltransferaseHomo sapiens (human)
thiopurine S-methyltransferase activityThiopurine S-methyltransferaseHomo sapiens (human)
S-adenosyl-L-methionine bindingThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolThiopurine S-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID269890DPPH radical scavenging activity in liposome2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Proton dissociation is important to understanding structure-activity relationships of gallic acid antioxidants.
AID49940Ability to inhibit Catechol O-methyltransferase from rat liver. kinetic inhibition Kis constant was reported1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors.
AID49926Ability to inhibit Catechol O-methyltransferase from rat liver at a concentration of 1 mM. Inhibition pattern was reported; Noncompetitive kinetics1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors.
AID269889DPPH radical scavenging activity in ethanol solution2006Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15
Proton dissociation is important to understanding structure-activity relationships of gallic acid antioxidants.
AID213093Inhibition of purified human kidney thiopurine methyltransferase (TPMT)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.
AID49935Ability to inhibit Catechol O-methyltransferase from rat liver. kinetic inhibition Kii constant was reported1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (50.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.23 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]